Aptorum Group (APM) Competitors $0.94 -0.02 (-2.18%) As of 04/30/2025 03:57 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APM vs. ALLR, NAII, CMMB, EDSA, SLGL, EQ, LPCN, CING, UBX, and BFRGShould you be buying Aptorum Group stock or one of its competitors? The main competitors of Aptorum Group include Allarity Therapeutics (ALLR), Natural Alternatives International (NAII), Chemomab Therapeutics (CMMB), Edesa Biotech (EDSA), Sol-Gel Technologies (SLGL), Equillium (EQ), Lipocine (LPCN), Cingulate (CING), Unity Biotechnology (UBX), and Bullfrog AI (BFRG). These companies are all part of the "pharmaceutical products" industry. Aptorum Group vs. Allarity Therapeutics Natural Alternatives International Chemomab Therapeutics Edesa Biotech Sol-Gel Technologies Equillium Lipocine Cingulate Unity Biotechnology Bullfrog AI Allarity Therapeutics (NASDAQ:ALLR) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, community ranking, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk. Which has higher valuation & earnings, ALLR or APM? Aptorum Group has higher revenue and earnings than Allarity Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllarity TherapeuticsN/AN/A-$11.90MN/AN/AAptorum Group$430K11.32-$2.83MN/AN/A Do institutionals and insiders have more ownership in ALLR or APM? 11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 3.8% of Aptorum Group shares are held by institutional investors. 0.1% of Allarity Therapeutics shares are held by company insiders. Comparatively, 64.0% of Aptorum Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more volatility and risk, ALLR or APM? Allarity Therapeutics has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500. Comparatively, Aptorum Group has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500. Does the media refer more to ALLR or APM? In the previous week, Allarity Therapeutics and Allarity Therapeutics both had 3 articles in the media. Allarity Therapeutics' average media sentiment score of 0.79 beat Aptorum Group's score of 0.56 indicating that Allarity Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allarity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aptorum Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer ALLR or APM? Aptorum Group received 40 more outperform votes than Allarity Therapeutics when rated by MarketBeat users. Likewise, 68.33% of users gave Aptorum Group an outperform vote while only 50.00% of users gave Allarity Therapeutics an outperform vote. CompanyUnderperformOutperformAllarity TherapeuticsOutperform Votes150.00% Underperform Votes150.00% Aptorum GroupOutperform Votes4168.33% Underperform Votes1931.67% Is ALLR or APM more profitable? Aptorum Group's return on equity of 0.00% beat Allarity Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Allarity TherapeuticsN/A -369.67% -100.06% Aptorum Group N/A N/A N/A SummaryAptorum Group beats Allarity Therapeutics on 7 of the 10 factors compared between the two stocks. Get Aptorum Group News Delivered to You Automatically Sign up to receive the latest news and ratings for APM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APM vs. The Competition Export to ExcelMetricAptorum GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.87M$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.4422.4818.48Price / Sales11.32242.70395.10103.59Price / CashN/A65.8538.1834.62Price / Book0.326.516.774.25Net Income-$2.83M$143.21M$3.22B$248.23M7 Day Performance-6.10%1.98%1.50%0.89%1 Month Performance7.56%6.89%4.01%3.53%1 Year Performance-82.93%-2.52%16.16%5.08% Aptorum Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APMAptorum Group0.9277 of 5 stars$0.94-2.2%N/A-82.1%$4.87M$430,000.000.0030Short Interest ↑Gap DownALLRAllarity Therapeutics0.3037 of 5 stars$1.03+9.6%N/A-96.9%$17.53MN/A0.0010NAIINatural Alternatives International0.8436 of 5 stars$2.61-6.1%N/A-52.0%$17.21M$121.85M-2.02290Gap DownHigh Trading VolumeCMMBChemomab Therapeutics3.585 of 5 stars$1.16+3.6%$9.00+675.9%+92.9%$16.66MN/A-1.1620Upcoming EarningsShort Interest ↓News CoverageGap UpEDSAEdesa Biotech3.0965 of 5 stars$2.38+5.3%$21.00+782.4%-47.6%$16.64MN/A-1.2720Short Interest ↓Positive NewsSLGLSol-Gel Technologies2.3656 of 5 stars$0.59+6.4%$5.00+754.7%+6.7%$16.30M$11.71M-1.7250Gap DownHigh Trading VolumeEQEquillium2.7926 of 5 stars$0.46-3.7%$3.00+559.1%-71.8%$16.26M$41.10M-3.2540Upcoming EarningsShort Interest ↓Positive NewsGap DownLPCNLipocine2.5453 of 5 stars$3.01+0.3%$10.00+232.2%-28.4%$16.10M$11.20M-3.9610Upcoming EarningsAnalyst ForecastNews CoverageCINGCingulate2.4774 of 5 stars$4.07-4.0%$30.67+653.5%+350.8%$16.04MN/A-0.2820Short Interest ↑UBXUnity Biotechnology4.1077 of 5 stars$0.94-3.1%$5.33+467.6%-26.6%$15.85M$240,000.00-0.7260Analyst RevisionBFRGBullfrog AI0.4706 of 5 stars$1.66flatN/A-43.6%$15.63M$60,000.00-1.954Short Interest ↑ Related Companies and Tools Related Companies ALLR Competitors NAII Competitors CMMB Competitors EDSA Competitors SLGL Competitors EQ Competitors LPCN Competitors CING Competitors UBX Competitors BFRG Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APM) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptorum Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptorum Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy APM Stock Free APM Stock Alerts